ADAM17 and pulmonary emphysema: In summary, the therapeutic targeting of ADAM17 represents an attractive strategy to tackle LAC and other conditions of the lung (e.g., asthma, emphysema), and for that matter, other cancers (e.g., CRC and pancreatic cancer) with aberrant ADAM17 activity and/or expression.